



The  
Patent  
Office

18 00 / 219

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

PCT / IB 00 / 00219

09/09/14 14:09:00

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 22 MAR 2000

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

*Andrew Gensy*

Dated 31 MAR 2000

**THIS PAGE BLANK (USPIC,**

Form 1/77

Patents Act 1977  
(Rule 16)**The  
Patent  
Office**23FEB99 E427325-4 D00019  
P000000000 - 9904004.0**Request for grant of patent**

(See the notes on the back of this form. You can also  
get an explanatory leaflet from the Patent Office to  
help you fill in this form)

**The Patent Office**Cardiff Road  
Newport  
Gwent NP9 1RH1. Your reference **P02096896 (G023948PT)**2. Patent application number  
(The Patent Office will fill in this part)**9904004.0**3. Full name, address and postcode of the or of  
each applicant (underline all surnames)**EUROPEAN MOLECULAR BIOLOGY LABORATORY  
POSTFACH 102209  
69012 HEIDELBERG  
GERMANY**

Patents ADP number (if you know it)

**7365943001**If the applicant is a corporate body, give the  
country/state of its incorporation**GERMANY**

4. Title of the invention

**TRANSLATION SYSTEM**

5. Name of your agent (if you have one)

**Carpmaels & Ransford**"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)**43 Bloomsbury Square  
London  
WC1A 2RA**

Patents ADP number (if you know it)

**83001**6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(day / month / year)8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an  
applicant, or
- c) any named applicant is a corporate body

**Y s**

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 17

Claim(s) 5

Abstract

Drawing(s) 10 910 8

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carmel Ransford*  
Carmmaels & Ransford

22nd February 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. Hugh Goodfellow

0171 242 8692

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## TRANSLATION SYSTEM

The present invention relates to a cell-free translation system. In particular, the invention relates to a cell-free translation system derived from cell extracts, that reproduces the synergism that occurs during translation *in vivo* between the *cap* and the  
5 *poly(A)* tail structures of the mRNA.

Translational control is an important mechanism for the regulation of gene expression during a variety of biological processes, including cellular metabolism (Hentze & Kuhn, (1996) P.N.A.S. USA 93: 8175-8182), cell differentiation (Ostareck *et al.*, 1997, Cell. 89: 597-606) and embryonic development (Wickens *et al.*, 1996, in Translation Control,  
10 Eds. Hershey, J.W.B., Mathews, M.B. and Sonenberg, N. (Cold Spring Harbour Lab. Press, Plainview, NY, pp. 411-450). Failure to regulate translation properly often leads to disease.

*In vivo*, two modifications in the mRNA, namely a *cap* structure at the 5' end and a *poly(A)* tail at the 3' end, act synergistically to promote mRNA translation (Gallie, 1991,  
15 Genes Dev. 5: 2108-2116). To date, research into the function of those structures and the synergism that occurs between them has been restricted by the lack of *in vitro* systems that accurately recapitulate these features.

Recently, a cell-free translation system that reproduces this synergism has been obtained from the unicellular eukaryote *Saccharomyces cerevisiae* (Iizuka *et al.*, 1994,  
20 Mol. Cell. Biol. 17: 7322-7330). Capped mRNAs were found to be translated 50-fold more efficiently than uncapped mRNAs in yeast lysate. Polyadenylated RNAs were found to be translated 140-fold more efficiently than non-polyadenylated RNAs. mRNAs containing both a 5' *cap* and a 3' *poly(A)* tail were found to be translated several hundred-fold more efficiently than mRNAs lacking both of these terminal sequences.

25 A cell-free translation system derived from animal cells that is capable of reproducing this synergism would be of great value for a number of reasons. Firstly, this would facilitate and enhance the validity of basic research into the factors and mechanisms involved in translational control in higher eukaryotes, including the regulation of translation by *cis*- and *trans*- acting factors, the molecular basis of synergism, mRNA

stability and polyadenylation. Second, species-specific differences in translational mechanisms could be evaluated. Such a system would also allow the improvement of large-scale protein synthesis, both with respect to the efficiency of translation and to the fidelity of post-translational modification.

## 5 Summary of the Invention

According to a first aspect of the present invention, there is provided a method for the *in vitro* translation of a ribonucleic acid template, said ribonucleic acid having both a 5' cap and a 3' poly A tail, said method comprising incubating a cell extract of a multicellular eukaryote with said ribonucleic acid template under conditions such that translation of the RNA template to produce its encoded protein by one or more components in the cell extract occurs and the amount of the encoded protein thus produced is greater than the total of (a) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 5' cap but no 3' poly A tail, plus (b) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 3' poly A tail but no 5' cap.

It has been found, surprisingly, that by combining a dechoriation procedure that has been previously used for the study of chromatin assembly (Becker *et al.*, 1994) with homogenisation and centrifugation conditions used to study translation (Scott *et al.*, 1979) a protocol results that allows the preparation of cell extract with greatly improved properties over conventionally known extracts for use in *in vitro* translation procedures.

The cell extract may be an animal cell extract, such as a mammalian cell, or an insect cell. Specific examples include cell extracts of *Drosophila*, *C. elegans*, rodent, rabbit (for example, reticulocyte cells), human (for example HeLa cells) and primate cells. The cells may be embryonic or adult or from a particular tissue such as the ovaries. Preferably, the cell extract is a *Drosophila* cell extract, most preferably a *Drosophila* embryo or ovary cell extract.

The extract exhibits properties that were previously unforeseen, such as the capability to reproduce the synergism that occurs during translation *in vivo* between the cap and the poly(A) tail structures of an mRNA molecule, and the capability to perform mRNA polyadenylation. In addition, the procedure is simple and allows the preparation of large

amounts of extract at low cost. This makes the system useful in both basic research and in commercial applications as is discussed in more detail below.

RNA templates suitable for use in the methods of *in vitro* translation of the invention may be recombinant or can be purified native templates. In preferred aspects of the invention, the poly(A) tail of the RNA template can be encoded in a DNA coding sequence which can be transcribed to generate an RNA template with a poly(A) tail of defined length. An alternative method of generating the poly(A) tail is the use of a poly(A) polymerase in an *in vitro* reaction to add the tail to the template as a post-transcriptional modification.

The 5' cap portion may be added co-transcriptionally to the RNA template by the RNA polymerase. A suitable protocol can be found in "Protocol and Applications Guide"; Promega, 2nd edition, p62. If the template is a purified native RNA template, the cap structure will already be in place.

According to a second aspect of the invention there is provided a method for the preparation of a *Drosophila* embryo extract comprising the steps of a) dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach; b) washing the embryos; c) homogenizing the embryos to produce a homogenate; d) centrifuging the homogenate; and e) recovering non-pelleted material from the centrifuged homogenate. This cell extract is particularly suited for use in the method of the first aspect of the invention.

The age of the embryo is not crucial to the method of the invention, although embryos of between the ages of 1 hour and 12 hours of development are preferred.

Before preparation of extract, the embryos should preferably be collected in a sieve and washed extensively with water to remove debris from the culture medium in which they have been laid. For preparation of extract, the embryos are washed with an aqueous buffer, preferably with fresh EW buffer (0.7% NaCl, 0.04% Triton X-100), and poured into a suitable vessel. An excess of buffer is then added and the embryos allowed to settle. At this stage, floating embryos should be discarded. For dechoriation, fresh buffer should be added and the embryo suspension agitated, preferably using a spinning

magnet or other suitable device. In all steps for the preparation of cell extract, ethanol-based buffers should be avoided.

For dechoriation, bleach is added to the embryo suspension, preferably at a concentration of about 3% by volume and the solution incubated for an appropriate time. Preferably, incubation is for between 1 and 9 minutes, most preferably 3 minutes.

Dechoriation may be carried out at a temperature of between 18 and 37°C. Preferably, dechoriation is carried out at about 25°C.

After dechoriation, embryos are preferably transferred to a sieve and washed extensively with water. Dechorionated embryos are then transferred to a suitable vessel (such as a beaker or cylinder) and buffer such as DE buffer (10mM HEPES pH 7.4, 5mM DTT) added. Floating embryos are discarded. Preferably, about 1 volume (with respect to the volume of settled embryos) of fresh buffer containing protease inhibitors is added to prevent proteolysis of components of the extract.

Embryos are then homogenised. Preferably, homogenisation is carried out at about 4°C. Most preferably, a Potter-Elvehjem homogeniser is used at about 1500 rpm (about 20 strokes). The homogenate should preferably be kept on ice to minimise proteolysis.

The homogenate is preferably centrifuged, ideally in an ultracentrifuge at 24,000 rpm (40,000g)/TLS-55 rotor/4°C/20 minutes. The clear interphase is taken, ideally by puncturing the tube with a syringe, and is transferred to a Falcon tube.

Glycerol may then be added to the extract, preferably to a 10% final concentration, and the extract aliquoted, frozen in liquid nitrogen and kept at -70°C for future use.

Drosophila ovaries may also be used to produce a cell extract. The procedure is as follows: adult female flies are manually dissected to obtain the ovaries, which should be placed in an eppendorf tube on ice in an aqueous medium, for example PBS. Ovaries are then allowed to settle, before transferring the ovaries slowly from an isotonic medium to a hypotonic medium. For example, the ovaries can be washed twice with around 12 volumes of a 1:1 mix of PBS:DEI buffer (DEI = 10mM HEPES pH 7.4, 5mM DTT, 1 x COMPLETE-Protease inhibitors from Boehringer Mannheim cat#1697498), and twice with 12 volumes of DEI. After washing, all the buffer is



removed and the ovaries manually homogenised using a plastic pestle. The homogenate can then be spun and the extract collected as described above for embryo extract.

According to a third aspect of the invention there is provided the extract of *Drosophila* embryos or ovaries, produced according to the method of the second aspect of the invention.

According to a fourth aspect of the invention there is provided a method for the *in vitro* translation of a ribonucleic acid template, comprising the steps of adding a ribonucleic acid template to a translation mix in the presence of the embryo or ovary extract of the third aspect of the invention to form a reaction mix and incubating the reaction mix for at least 90 minutes at between 18°C and 28°C. Preferably, the reaction mix is incubated for at least 90 minutes at 25°C.

By reaction mix is meant a solution of components necessary for *in vitro* translation to occur. Such components may include any of the following: spermidine, amino acids, creatine phosphate, creatine kinase, dithiothreitol (DTT), buffer,  $\text{Mg}(\text{OAc})_2$ , KOAc, tRNA, *Drosophila* embryo extract and RNA template. This reaction mix should preferably be prepared fresh. All the components of the reaction mix, except the creatine kinase, should be dissolved in distilled water to their required concentrations.

Preferably, the buffer is HEPES buffer, although any buffer with a low concentration of salt (below 10mM) may be used. HEPES buffer is most preferably used at a final concentration of about 24mM. As used herein, the term "final concentration" means the concentration of the component that is present in the *in vitro* translation mix. These concentrations are optimal for the translation reaction to take place.

Preferably, said tRNA is calf liver tRNA, at a final concentration of below 150µg/ml, most preferably about 100µg/ml.

Preferably, the final concentration of spermidine is about 0.1mM. For amino acids, final concentration is about 60µM. For creatine phosphate, the concentration can be in the range 17-23mM. It is shown herein (see Figure 6) that it is preferable to use fresh or newly thawed creatine phosphate. The level of translation doubles when fresh creatine phosphate is used.

Creatine kinase should be used at a concentration of about 0.08mg/ml.

The concentrations of DTT,  $\text{Mg}(\text{OAc})_2$  and KOAc should be optimised for each individual mRNA template, as will be appreciated by those skilled in the art. For example, for translation of M1414WT (bgal) (see below), ideal concentrations are DTT, 1.2mM;  $\text{Mg}(\text{OAc})_2$ , 0.6mM; and KOAc, 60mM. For c-Luc-a, ideal concentrations are  
 5 DTT, 0mM;  $\text{Mg}(\text{OAc})_2$ , 0.4mM; and KOAc, 30mM.

However, final concentration of  $\text{Mg}(\text{OAc})_2$  can be in the range 0-3mM. KOAc can range between 0 and 200mM. DTT can range between 0-4mM.

Embryo or ovary extract should preferably be used at a concentration of about 40% by  
 10 volume.

Optimal RNA template concentration will vary depending upon the RNA type. The skilled artisan will appreciate that optimisation of the system may be easily performed for a particular RNA species of choice using routine procedures. For example, for the species c-luc-a (coding for firefly luciferase) a concentration of about 3.2ng/ $\mu\text{l}$  is  
 15 optimal. The mRNA template should preferably be capped and should contain a *poly(A)* tail of more than 31 adenine nucleotides (more preferably 70-100 adenines).

For each mRNA species, preliminary reactions should be performed so as to obtain a curve of translation efficiency with differing amounts of mRNA. An amount of mRNA should be used in the linear range of translation. In the examples described herein, test  
 20 reactions were performed with M1414WT (bgal) [this codes for the  $\beta$ -galactosidase enzyme and contains 5' and 3' UTR sequences from *Drosophila oskar* mRNA], c-Luc-a and Luc mRNA (Promega).

Reaction mix prepared in this fashion contributes to the advantageous features of the method of this aspect of the invention, namely reproducing the synergy between the 5'  
 25 *cap* and 3' *poly(A)* tail of the RNA molecule for translation.

Additionally to this synergy, the level of translation is enhanced, so leading to a greater production of protein. The fidelity of post-translational modification appears also to be retained, differentiating the system of the present invention over that described previously in yeast (Iizuka *et al.*, 1994). Although yeasts do possess enzymes that are

capable of effecting the post-translational modification of proteins, the type and extent of modification tends to differ from that found in higher eukaryotes. Consequently, the *Drosophila* system of the present invention generates proteins modified similarly to the state in which they are found *in vivo*.

- 5 The incubation step is preferably performed for sufficient time to allow the translation reaction to proceed to the extent desired. Preferably, the incubation step is performed for at least about 90 minutes.

Ranges of suitable concentrations of components of the reaction mix, along with optimal concentrations, are given below in Table 1. These concentrations were optimised for luc and c-luc-a mRNA species, coding for the firefly luciferase enzyme.

**TABLE 1**

	Range tested	Optimal	RNA	Observations
Creatine phosphate	0-168mM	17-23mM	Luc	Use fresh (thaw only once)
Creatine kinase	0-1.68 mg/ml	0.08 mg/ml	Luc	
KOAc	0-200mM	74mM	Luc	Should be optimised for each RNA template
Mg(OAc) <sub>2</sub>	0-3mM	0.3mM	Luc	Should be optimised for each RNA template
Spermidine	0-1.8mM	0.1mM	c-Luc-a	
Amino acids	0-100 µM	60 µM	c-Luc-a	
DTT	0-4mM	0mM	c-Luc-a	Should be optimised for each RNA template
tRNA	0-150 µg/ml	100 µg/ml	Luc	
Temperature	18-37°C	25°C	c-Luc-a	

Ideally, the *in vitro* translation reaction is performed in a final volume of about 12.5 microlitres. Below, in Table 2, the volume of stock concentrations is given in order to make up a reaction volume of 12.5 microlitres.

## 5 TABLE 2

- Final volume = 12.5  $\mu$ l
- Mix per reaction:

	Volume ( $\mu$ l)	Final conc.
2.5mM spermidine	0.5	0.1mM
1mM-amino acids (Promega)	0.75	60 $\mu$ M
1 M creatine phosphate (fresh or newly thawed)	0.21	16.8mM
10 $\mu$ g/ $\mu$ l creatine kinase	0.1	80 ng/ $\mu$ l
0.1 M DTT	0.15	1.2mM
1 M HEPES pH 7.4	0.3	24mM
4.13mM Mg(OAc) <sub>2</sub>	1.8	0.6mM
1 M KOAc	0.75	60mM
1.1 $\mu$ g/ $\mu$ l calf liver tRNA	1.1	100ng/ $\mu$ l
Embryo extract	5	40%
RNA template	1	3.2ng/ $\mu$ l
H <sub>2</sub> O	to 12.5 $\mu$ l final	

According to a fifth aspect of the invention there is provided the use of *Drosophila* extract according to the third aspect of the invention in a method of *in vitro* translation of a ribonucleic acid template, such as the methods of the first and fourth aspects of the invention. The method reproduces the synergism exhibited *in vivo* between the 5' cap and 3' *poly(A)* tail of the ribonucleic acid template.

According to a sixth aspect of the invention there is provided the use of *Drosophila* extract according to the third aspect of the invention or method of first or the fourth aspects of the invention to screen for compounds that either a) decrease the translation, polyadenylation and/or stability of all mRNA species, or of specific mRNAs; b) potentiate the translation, polyadenylation and/or stability of all mRNA species, or of specific mRNAs; or c) decrease or potentiate the synergism between the 5' cap and the 3' *poly(A)* tail of the mRNA. Suitable compounds may interact (either directly or indirectly) with only one of the 5' cap or *poly(A)* structures. Preferably, compounds identified in such a screen have an effect on translational control in higher eukaryotes, in particular insects. This screening method has advantages over prior art methods because the synergy exhibited between cap and *poly(A)* structures mimics the features of *in vivo* translation and allows the screening in an *in vitro* system for modifiers effecting translation that are significantly more likely to function *in vivo*.

According to a seventh aspect of the invention there is provided a compound identified by a screen according to the sixth aspect of the invention. Suitable compounds may be natural or synthetic, for example, an aptamer, or a peptide and may be useful for therapy of diseases and for the control of plagues and diseases caused by insects, for example malaria and plant pestilence. For example, the compound may that interact with 5' cap or 3' *poly(A)* structures of an mRNA template or affect in some way the synergism between the 5' cap and 3' *poly(A)* tail of an mRNA template. In some instances, compounds may be specific for a certain group of mRNA templates, or for mRNA templates within a certain species. It is envisaged that such compounds will prove useful in the control of plagues and diseases caused by insects, for example malaria and plant pestilence, by interfering with the expression of certain essential insect proteins.

According to an eighth aspect of the invention there is provided the use of the *Drosophila* extract according to the third aspect of the invention or method of the first or

fourth aspects of the invention in research into the regulation and function of post-transcriptional mRNA modification or post-translational protein modification.

After the identification of the polypeptides that are responsible for the synergism between the 5' cap and the 3' poly(A) structures of the mRNA, it is possible to study the productive interactions between them and to define the domains and amino acid residues that are responsible for these interactions. It will, then, become possible to design chimeric molecules that comprise the effector domains from these polypeptides fused to other polypeptides of interest. Upon interaction of the polypeptides of interest, the effector domains would promote the translation of a reporter mRNA, such as luciferase. The level or degree of interaction would be quantified by measuring the amount of light that is produced. In order to aid the study of interactions of interest, appropriate components such as *Drosophila* extract, reporter mRNA and reaction mix may be provided in the form of a kit.

According to a ninth aspect of the invention there is provided a kit for the analysis of *in vitro* translation, polyadenylation and/or stability of ribonucleic acid. The kit should contain *Drosophila* extract according to the third aspect of the invention along with stock solutions of all the other components of the translation mix in appropriate quantities. The kit will therefore in addition comprise any one or all of spermidine, amino acids, creatine phosphate, creatine kinase, optionally dithiothreitol (DTT), buffer,  $\text{Mg}(\text{OAc})_2$ , KOAc, tRNA, and RNA template.

As noted above, preferably, the buffer is HEPES buffer, the tRNA is calf liver tRNA and ideally, the creatine phosphate is made fresh. However, creatine phosphate may be supplied in powdered form in the kit for dissolution in distilled water as and when required for use.

Generally, an RNA template will not be supplied as part of the kit, since in the main part, it is envisaged that the kit will be purchased for the purposes of experimental research. However, a control RNA template may be included in the kit so that a user can ensure that the translation reaction is proceeding appropriately. For example, comparison with a control RNA template may be used to optimise the concentration of test RNA, DTT,  $\text{Mg}(\text{OAc})_2$  and KOAc that is to be used.

The kit preferably also contains appropriate instructions to enable a user to perform the *in vitro* translation reaction appropriately.

The invention will now be described in detail with particular reference to a Luc mRNA template. As will be clear to the person of skill in the art, variations from the described  
5 protocol may be made without departing from the scope of the invention.

All references cited herein are hereby incorporated by reference in their entireties.

### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows comparative results of translation levels and levels of synergy found between 5' *cap* and 3' *poly(A)* tail of an RNA template.

10 Figure 2 is an expanded scale of the results of Figure 1.

Figure 3 shows optimisation of  $Mg^{2+}$  concentration.

Figure 4 shows optimisation of  $K^{+}$  concentration.

Figure 5 shows optimisation of creatine kinase concentration.

Figure 6 shows how percentage translation is improved by using fresh creatine  
15 phosphate.

Figure 7 shows optimisation of creatine phosphate concentration.

Figure 8 shows optimisation of spermidine concentration.

Figure 9 shows optimisation of tRNA concentration.

Figure 10 shows optimisation of temperature, amino acid concentration and DTT  
20 concentration using c-luc-a RNA.

### EXAMPLES

#### Example 1: Preparation of extracts from *Drosophila* embryos

Extracts from 1h30', 3h, 6h and 12h embryos were prepared with similar results.

Embryos were laid by 2-3 day old adult *Drosophila* flies on agar-apple juice plates (2.9% Agar; 30% Apple Juice; 4.4% Rubensirup; 0.25% Nipagin). The plates, spread with some fly food (220ml deionized water, 1.4ml Propionic acid; 150g dry yeast), were left overnight for embryo laying). Embryos from 16 agar-apple juice plates were  
 5 collected in a pile of sieves (the first with a cut-off size of an adult-fly, the second with a cut-off size of a fly appendix [e.g.: a leg, a head or an antenna]; the last with a cut-off size of a single embryo) and washed extensively (~5-10 minutes) with tap water to remove debris coming from the plates.

Embryos were subsequently washed with freshly prepared isotonic EW buffer (0.7%  
 10 NaCl, 0.04% TritonX-100). To do this, embryos were transferred to a 500ml cylinder containing EW buffer, and were allowed to settle for ~3-5 minutes (roughly the time needed for 90% of the embryos to pellet by gravity) and were then washed twice with 500ml EW Buffer. Floating embryos were eliminated by suction.

Embryos were dechorionated in the 500 ml cylinder at room temperature (~20-25°C)  
 15 with 260ml of EWB (0.7% NaCl, 0.04% TritonX-100, 3% Sodium Hypochlorite) for 3 minutes under vigorous agitation provided by a magnetic stirrer. Sodium Hypochlorite was from Sigma, Thomas Chemikalien; or U.S. CHLOROX. No significant change in the translation efficiency of the extract was noted for different bleach types.

Dechorionated embryos were transferred back to the sieves, and were vigorously and  
 20 extensively washed with tap water (by flushing a strong stream of water for about 5-10 minutes). Washed embryos were settled by gravity twice with 100 ml of DE buffer (10mM HEPES pH 7.4, 5mM DTT) in a 100ml cylinder. Floating embryos were discarded, and an equivalent of one volume (with respect to the settled embryos) of DEI buffer (10mM HEPES pH 7.4, 5mM DTT, 1x COMPLETE-Protease Inhibitors from  
 25 Boehringer Mannheim cat# 1697498) was added.

Embryos in DEI buffer were homogenised in a cold room (~4°C) by 20 strokes of a Potter-Elvehjem homogeniser at 1500 rpm and the homogenate was kept on ice. The homogenate was spun in a table-top ultracentrifuge (Beckmann) at 24000 rpm (40000x g) in a TLS-55 rotor at 4 C for 20 minutes. The clear aqueous interphase was taken by  
 30 puncturing the tube with a syringe, and was transferred to a Falcon tube. Glycerol was



added to 10% final, and the extract was aliquoted, flash-frozen in liquid nitrogen and stored at  $-70^{\circ}\text{C}$ .

### Example 2:

#### 2.1 *In vitro* translation

5 A typical experiment is shown below.

The reaction is performed in a final volume of 12.5  $\mu\text{l}$ , containing the following mix (a):

	<u>volume (<math>\mu\text{l}</math>)</u>	<u>Final conc.</u>	
	0.5	0.1 mM	
10 2.5 mM spermidine	0.75	60 $\mu\text{M}$	
1 mM amino acids	0.21	16.8 mM	
1 M creatine phosphate (fresh or newly thawed)			
10 $\mu\text{g}/\mu\text{l}$ creatine Kinase	0.1	80 $\text{ng}/\mu\text{l}$	
0.1 M DTT	Y	0 - 1.2 mM	(b) (*)
15 1 M HEPES pH 7.4	0.3	24 mM	
4.13 mM $\text{Mg}(\text{OAc})_2$	Z	0.3 - 0.6 mM	(b) (*)
1 M KOAc	W	30 - 80 mM	(b) (*)
1.1 $\mu\text{g}/\mu\text{l}$ calf liver tRNA	1.14	100 $\text{ng}/\mu\text{l}$	
embryo extract	5	40%	
20 RNA template	X	(c)	
$\text{H}_2\text{O}$	to 12.5 $\mu\text{l}$ final		

The reaction was incubated at  $25^{\circ}\text{C}$  for 90 min.

(a) A master mix should be prepared for as many samples as it is required.

(b) Should be optimised for each mRNA template.

25 (c) The mRNA template should be capped and should contain a poly(A) tail of more than 31 A's (usually 70-100 A's), although mRNAs without a poly(A) tail are also translated albeit at lower efficiency. A curve of translation with different amounts of RNA should be performed to use an amount in the linear range of translation.

(\*) Concentrations (mM) optimal for:

	<u>RNA</u>	<u>DTT</u>	<u>Mg(OAc)<sub>2</sub></u>	<u>KOAc</u>
	M1414WT (bgal)	1.2	0.6	60
	c-Luc-a	0	0.4	30
5	mLuc-a	0	0.6	80
	c-CAT-a	1.2	0.6	60

10 *M1414WT* RNA encodes for the  $\beta$ -galactosidase enzyme (bgal) and contains 5' and 3' UTR sequences from *Drosophila oskar* mRNA. *c-Luc-a* encodes for the firefly luciferase enzyme. *mLuc-a* encodes for the firefly luciferase enzyme, and contains the 5' UTR of *Drosophila msl-2* mRNA. *c-CAT-a* encodes for the chloramphenicol acetyl transferase enzyme. All RNAs are capped and polyadenylated.

Spermidine is from SIGMA, cat# S-0381.

Amino acids were obtained from Promega (cat# L4461), or can be self-made from a SIGMA kit (cat# LAA-21).

15 Creatine Kinase is from Boehringer Mannheim (cat# 126969). The stock solution is prepared at 10 mg/ml in 50% glycerol, 20 mM HEPES-KOH pH 7.4.

Using this protocol, together with the extract described in Example 1, high levels of translation and synergy can be obtained, compared to other methods (see Figure 1).

## 2.2 Optimisations

20 Ranges of suitable concentrations, along with optimal concentrations, are given below.

The method of Example 1 was followed (not that of Scott *et al*), and one concentration value was varied for each experiment. Luc RNA from Promega was used for these experiments, except where otherwise stated.

25 Figure 3 shows optimisation of  $Mg^{2+}$  concentration. Optimum concentration was found to be 0.3mM. Figure 4 shows optimisation of  $K^+$  concentration. Optimum concentration was found to be 74mM for this system.

Figure 5 shows optimisation of creatine kinase concentration. Optimum concentration was found to be 0.08mg/ml for this system.

Figure 6 shows how % translation could be improved more than two times by using fresh creatine phosphate.

- 5 Figure 7 shows optimisation of creatine phosphate concentration. Optimum concentration was found to be 23mM for this system.

Figure 8 shows optimisation of spermidine concentration. Optimum concentration was found to be 0.1mM for the c-luc-a RNA system.

- 10 Figure 9 shows optimisation of tRNA concentration. Optimum concentration was found to be 100µg/ml for the luc RNA system.

Figure 10 shows optimisation of temperature, amino acid concentration and DTT concentration using c-luc-a RNA. Optimum temperature was found to be 25°C. Optimum amino acids concentration was found to be 60µM. Optimum DTT concentration was found to be 0mM.

	<u>Range tested</u>	<u>Optimal</u>	<u>RNA</u>	<u>Observations</u>
Creatine phosphate	0 - 168 mM	17 - 23 mM	Luc	Use fresh (thaw only once)
Creatine kinase	0 - 1.68 mg/ml	0.08 mg/ml	Luc	
KOAc	0 - 200 mM	74 mM	Luc	Should be optimised for each RNA template
Mg(OAc) <sub>2</sub>	0 - 3 mM	0.3 mM		
Spermidine	0 - 1.8 mM	0.1 mM	c-Luc-a	0.3 mM or no spermidine also works for some mRNAs
amino acids	0 - 100 µM	60 µM	c-Luc-a	
DTT	0 - 4 mM	0 mM	c-Luc-a	Should be optimised for each RNA template
tRNA	0 - 150 µg/ml	100 µg/ml	Luc	

Temperature	18 - 37°C	25 °C	c-Luc-a	
-------------	-----------	-------	---------	--

**Example 3: Comparison between method of the invention and that described in Scott *et al.*, (1979) *Biochemistry*, 18(8): 1588-1594.**

Drosophila embryo extracts were prepared in parallel either according to the method described in Scott *et al.* (1979) or to the method of the invention. These extracts were  
 5 assayed for translation using either the conditions described in Scott *et al.* (1979) or the conditions described above.

Briefly, the Scott protocol consisted in dechorionating the embryos in a solution of 50% ethanol/50% chlorox for 1 m in under agitation, washing the embryos 5 times in PBS after dechorionation using a table-top centrifuge at top speed to obtain the embryo pellet  
 10 and homogenising the embryo pellet in 10mM HEPES pH7.4, 6mM  $\beta$ -mercaptoethanol.

The extracts obtained using this method were used in an *in vitro* translation reaction using either the conditions described in Example 2.1, those described by Scott *et al* (1979) or those described by Scott with an increased time of translation. The RNA used for translation encoded the firefly luciferase and contained either a cap (c), a poly(A)  
 15 (a), or both (c-a). The results (Figures 1 and 2) indicate that by using our extract in our *in vitro* translation conditions a high degree of translation and synergism was obtained. When the Scott extract was used under Scott's *in vitro* translation conditions, no synergism was obtained and a very low level of translation was observed. Using combination of both extracts with either ours or Scott's *in vitro* translation conditions,  
 20 low levels of translation with various degrees of synergy were obtained. Any apparent synergy in this figure exhibited by the Scott extract using our conditions is believed only to be because the very low level of translation seen gives unreliably low levels of luciferase activity. Accordingly, the (c), (a) and (c-a) figures cannot be compared. These data indicate that the combination of our extract (Example 1) with our *in vitro*  
 25 translation conditions (Example 2.1) make possible a high degree of translation and synergism.

Comparative results of translation levels and levels of synergy found between the 5' cap and the 3' poly(A) tail of the mRNA template are shown in Figures 1 and 2.

Translation levels using the Scott method were very low. Translation levels using the extract and method of the invention were high and the level of synergy noted was also high (12x and 15x). Figure 2 shows the results of Figure 1 on an expanded scale.

### References

- 5 Becker PB, Tsukiyama T and Wu C (1994). Chromatin assembly extracts from *Drosophila* embryos. *Methods Cell Biol.* 44:207-23.

Scott, M. P., Storti, R. V., Pardue, M. L. and Rich A. (1979) Cell-free protein synthesis in lysates of *Drosophila melanogaster* cells. *Biochem.* 18: 1588-1594.

CLAIMS

1. A method for the *in vitro* translation of a ribonucleic acid template, said ribonucleic acid having both a 5' cap and a 3' poly A tail, said method comprising incubating a cell  
5 extract of a multicellular eukaryote with said ribonucleic acid template under conditions such that translation of the RNA template to produce its encoded protein by one or more components in the cell extract occurs and the amount of the encoded protein thus produced is greater than the total of (a) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 5' cap but no  
10 3' poly A tail, plus (b) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 3' poly A tail but no 5' cap.
2. The method according to claim 1 wherein the cell extract is an animal cell extract.
- 15 3. The method according to claim 2 wherein the cell extract is a mammalian cell extract.
4. The method according to claim 3 wherein the cell extract is a human cell extract.
5. The method according to claim 2 wherein the cell extract is an insect cell extract.
- 20 6. The method according to claim 5 wherein the cell extract is a *Drosophila* cell extract.
7. The method according to claim 6 wherein the cell extract is a *Drosophila* embryo cell extract.
- 25 8. The method according to claim 7 wherein the *Drosophila* embryo cell extract is prepared by a method comprising dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach.
- 30 9. The method according to claim 8 wherein the detergent is Triton X-100 and the bleach is sodium hypochlorite.

10. The method according to either of claims 8 or 9 which further comprises after dechorionating, the steps of washing the embryos; homogenizing the embryos to produce a homogenate; centrifuging the homogenate; and recovering non-pelleted material from the centrifuged homogenate.
- 5
11. The method according to claim 6 wherein the cell extract is a *Drosophila* ovary cell extract.
- 10
12. The method according to claim 11 wherein the *Drosophila* ovary cell extract is prepared by a method comprising (a) obtaining *Drosophila* ovaries in isotonic medium; (b) washing the ovaries so as to transfer the ovaries slowly from isotonic medium to hypotonic medium, such that the volume of the ovaries increases; (c) homogenising the ovaries to produce a homogenate; (d) centrifuging the homogenate to form an ovary cell extract; and (e) recovering non-pelleted material from the centrifuged homogenate.
- 15
13. The method according to any one of the preceding claims wherein said conditions comprise the presence of the following: creatine phosphate, creatine kinase, potassium and magnesium salts, spermidine, amino acids, a reducing agent, and tRNA.
- 20
14. The method according to any one of the preceding claims wherein said conditions comprise a temperature in the range of 18° to 37°C, and said incubating is for at least 90 minutes.
- 25
15. The method according to any one of the preceding claims wherein said incubating is at 25°C.
16. A method for the preparation of a *Drosophila* embryo extract comprising:
- 30
- a) dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach;
  - b) washing the embryos;
  - c) homogenizing the embryos to produce a homogenate;
  - d) centrifuging the homogenate; and
  - e) recovering non-pelleted material from the centrifuged homogenate.

17. A method for the preparation of a *Drosophila* ovary cell extract comprising (a) obtaining *Drosophila* ovaries in isotonic medium comprising detergent and bleach; (b) washing the ovaries so as to transfer the ovaries slowly from isotonic medium to hypotonic medium, such that the volume of the ovaries increases; (c) homogenising the ovaries to produce a homogenate; (d) centrifuging the homogenate to form an ovary cell extract; and (e) recovering non-pelleted material from the centrifuged homogenate.
18. A method according to either of claims 16 or 17, wherein said detergent is non-ionic.
19. A method according to any one of claims 16-18, wherein said homogenising is performed in the presence of protease inhibitors.
20. A method according to any one of claims 16-19 wherein said buffer is EW buffer (0.7% NaCl, 0.4% Triton X-100).
21. A method according to any one of claims 16-20, wherein said embryos or ovaries are incubated in said isotonic buffer for between 1 and 9 minutes.
22. A method according to claim 21, wherein said embryos or ovaries are incubated for about 3 minutes.
23. A method according to any one of claims 16-22, wherein said embryos or ovaries are incubated at between 18 and 37°C.
24. A method according to claim 23, wherein said embryos or ovaries are incubated at about 25°C.
25. A method according to any one of claims 16-24 wherein said embryos or ovaries are homogenised at about 4°C.
26. A method according to any one of claims 16-25 additionally comprising the step of adding glycerol to the recovered non-pelleted material to a concentration of about 10% by volume.
27. A method for the *in vitro* translation of a ribonucleic acid template, said method comprising the steps of:



- a) adding a ribonucleic acid template to a translation mix in the presence of an embryo extract according to any one of claims 16-26 or an ovary cell extract according to any one of claims 17-26, to form a reaction mix,
- b) incubating the reaction mix for at least 90 minutes.
- 5 28. A method according to claim 27, wherein said reaction mix comprises spermidine, amino acids, creatine phosphate, creatine kinase, dithiothreitol (DTT), buffer,  $\text{Mg}(\text{OAc})_2$ , KOAc, tRNA, Drosophila embryo extract, and RNA template.
- 10 29. A method according to claim 28, wherein said buffer is hypotonic buffer (10mM HEPES pH7.4, 5mM DTT).
30. A method according to either of claims 28 or 29, wherein said tRNA is calf liver tRNA.
- 15 31. A method according to any of claims 28-30, wherein the concentrations of the components of said reaction mix are as follows: spermidine, about 0.1mM; amino acids, about 60 $\mu\text{M}$ ; DTT, 0-4mM; creatine phosphate, 17-23mM; creatine kinase, 0.08mg/ml; buffer, about 24mM;  $\text{Mg}(\text{OAc})_2$ , 0-3mM; KOAc, 0-200mM; calf liver tRNA, 0-150 $\mu\text{g}/\text{ml}$ ; embryo extract, about 40% and RNA template, 1-3ng/ $\mu\text{l}$ .
- 20 32. A method according to claim 31, wherein the components of said reaction mix are as follows: spermidine, 0.1mM; amino acids, 60 $\mu\text{M}$ ; DTT, 0-4mM; creatine phosphate, 17-23mM; creatine kinase, 0.08mg/ml; HEPES buffer, 24mM;  $\text{Mg}(\text{OAc})_2$ , 0-3mM; KOAc, 60mM; calf liver tRNA, 100 $\mu\text{g}/\text{ml}$ ; embryo extract, 40% and RNA template, 3.2ng/ $\mu\text{l}$ .
33. A method according to any one of claims 27-32, wherein said reaction mix is prepared fresh.
- 25 34. A method according to any one of claims 28-33, wherein said creatine phosphate is prepared fresh or is newly thawed.

35. The method according to any one of claims 27-34 wherein said ribonucleic acid template is capped and contains a poly A tail of at least 30 adenine nucleotides in length.

5 36. A *Drosophila* embryo cell extract or ovary cell extract produced by the method of any one of claims 16-26.

37. Use of *Drosophila* extract according to claim 36 in a method of *in vitro* translation of a ribonucleic acid template.

10 38. A method according to any one of claims 1-15 wherein said cell extract is prepared according to the method of any one of claims 16 to 26.

39. A method of identifying a candidate molecule that increases or decreases the amount of a produced translation product, comprising:

15 a) performing the method according to any one of claims 1-15, 27-35 or 38 wherein said conditions or reaction mix comprise the presence of one or more candidate molecules being screened for the ability to increase or decrease the amount of the encoded protein that is produced; and

b) identifying any one or more candidate molecules that increase or decrease the amount of the encoded protein that is produced relative to the amount of the encoded protein that is produced in the absence of the one or more candidate molecules.

20

40. A purified candidate molecule that is identified according to the method of claim 39.

41. A kit for *in vitro* translation of ribonucleic acid comprising the following ingredients: spermidine, amino acids, creatine phosphate, creatine kinase, optionally dithiothreitol, 25 buffer,  $Mg(OAc)_2$ , KOAc, tRNA, *Drosophila* embryo or ovary cell extract according to claim 36, and RNA template.

42. A kit according to claim 41, wherein said buffer is HEPES buffer.


43. A kit according to either of claims 41 or 42, wherein said tRNA is calf liver tRNA.

1/10

**Experiment E-872 Blow-up (one set of data eliminated)**

c= cap, a = poly(A), c-a = cap and poly(A)

Synergism = fold over the sum of c+a value




**FIG. 1**

THIS PAGE BLANK (0011)


Experiment E-972

**c= cap, a = poly(A), c-a = cap and poly(A)  
Synergism = fold over the sum of c+a value**



**THIS PAGE BLANK (US. ...**

3/10




**FIG. 3**

● Luc RNA FROM PROMEGA  
FOR c-luc-a OPTIMAL IS ALSO 0.3mM (THOMAS' DATA)

**THIS PAGE BLANK (USPIC,**

---





**FIG. 4**

- Luc RNA FROM PROMEGA
  - FOR c-luc-a RNA OPTIMAL IS 40mM (THOMAS' DATA)
- MERGE OF 2 ≠ EXP.

**THIS PAGE BLANK (USPTO,**

5/10




FIG. 5


**THIS PAGE BLANK (USPTO)**

---

6/10

■ % translation

FIG. 6




CP (28 mM)

● Luc RNA FROM PROMEGA

**THIS PAGE BLANK (USFIC)**

7/10




● Luc RNA FROM PROMEGA  
MERGE OF 2 # EXP.

FIG. 7

**THIS PAGE BLANK (CONT.)**



8/10




**FIG. 8**

**THIS PAGE BLANK (USPTO)**


---

9/10



Luc RNA FROM PROMEGA

**THIS PAGE BLANK (U.S. ...)**



**FIG. 10**

**THIS PAGE BLANK (USPTO)**